Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia

Paul Yeh, Tane Hunter, Devbarna Sinha, Sarah Ftouni, Elise Wallach, Damian Jiang, Yih-Chih Chan, Stephen Q. Wong, Maria Joao Silva, Ravikiran Vedururu, Kenneth Doig, Enid Lam, Gisela Mir Arnau, Timothy Semple, Meaghan Wall, Andjelija Zivanovic, Rishu Agarwal, Pasquale Petrone, Kate Jones, David Westerman, Piers Blombery, John F. Seymour, Anthony T. Papenfuss, Mark A. Dawson, Constantine S. Tam and Sarah-Jane Dawson ()
Additional contact information
Paul Yeh: Peter MacCallum Cancer Centre
Tane Hunter: Peter MacCallum Cancer Centre
Devbarna Sinha: Peter MacCallum Cancer Centre
Sarah Ftouni: Peter MacCallum Cancer Centre
Elise Wallach: Peter MacCallum Cancer Centre
Damian Jiang: Peter MacCallum Cancer Centre
Yih-Chih Chan: Peter MacCallum Cancer Centre
Stephen Q. Wong: Peter MacCallum Cancer Centre
Maria Joao Silva: Peter MacCallum Cancer Centre
Ravikiran Vedururu: Peter MacCallum Cancer Centre
Kenneth Doig: Peter MacCallum Cancer Centre
Enid Lam: Peter MacCallum Cancer Centre
Gisela Mir Arnau: Peter MacCallum Cancer Centre
Timothy Semple: Peter MacCallum Cancer Centre
Meaghan Wall: Victorian Cancer Cytogenetics Service, St Vincent’s Hospital
Andjelija Zivanovic: Peter MacCallum Cancer Centre
Rishu Agarwal: Peter MacCallum Cancer Centre
Pasquale Petrone: Peter MacCallum Cancer Centre
Kate Jones: Peter MacCallum Cancer Centre
David Westerman: Peter MacCallum Cancer Centre
Piers Blombery: Peter MacCallum Cancer Centre
John F. Seymour: Peter MacCallum Cancer Centre
Anthony T. Papenfuss: Peter MacCallum Cancer Centre
Mark A. Dawson: Peter MacCallum Cancer Centre
Constantine S. Tam: Peter MacCallum Cancer Centre
Sarah-Jane Dawson: Peter MacCallum Cancer Centre

Nature Communications, 2017, vol. 8, issue 1, 1-7

Abstract: Abstract Several novel therapeutics are poised to change the natural history of chronic lymphocytic leukaemia (CLL) and the increasing use of these therapies has highlighted limitations of traditional disease monitoring methods. Here we demonstrate that circulating tumour DNA (ctDNA) is readily detectable in patients with CLL. Importantly, ctDNA does not simply mirror the genomic information contained within circulating malignant lymphocytes but instead parallels changes across different disease compartments following treatment with novel therapies. Serial ctDNA analysis allows clonal dynamics to be monitored over time and identifies the emergence of genomic changes associated with Richter’s syndrome (RS). In addition to conventional disease monitoring, ctDNA provides a unique opportunity for non-invasive serial analysis of CLL for molecular disease monitoring.

Date: 2017
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/ncomms14756 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:8:y:2017:i:1:d:10.1038_ncomms14756

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/ncomms14756

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().